Cytosorbents (CTSO) CEO Phillip Chan Buys $100K of Stock

Phillip Chan, the Chief Executive Officer of CTSO, made a significant insider purchase on June 12, 2026. Chan acquired 251,136 shares of the company at a price of $0.4 per share, amounting to a total value of $100,454.4. This transaction was not part of a pre-arranged trading plan.

Other Institutional Activity in CTSO

Several institutional investors have also adjusted their positions in CTSO. Vanguard Capital Management LLC significantly increased its holdings by adding 1,879,989 shares, bringing its total to 1,879,989 shares valued at approximately $1,064,074. Meanwhile, Avenir Corp reduced its stake by 14,323 shares, leaving it with 5,215,776 shares worth about $2,953,694. Skylands Capital, LLC cut its position by 147,017 shares, ending with 1,707,498 shares valued at $966,956. Neuberger Berman Group LLC added 57,367 shares to hold a total of 1,683,007 shares worth $950,776. BlackRock, Inc. grew its position by 12,441 shares, resulting in 782,992 shares valued at $443,408.

Cytosorbents Corporation Stock Down 93.0%

Shares of CTSO were trading near $0.4. The stock has seen various movements as institutional investors adjust their positions. The activity in the stock reflects ongoing interest and varied strategies from different funds.

Insider Buying and Selling at Cytosorbents Corporation

In addition to the recent purchase by Phillip Chan, there have been other insider transactions. On June 15, 2026, Chan bought an additional 10,333 shares at $0.43 per share. Previously, on November 18, 2025, Chan made two identical purchases of 100,000 shares each at $0.64 per share. In contrast, Peter Mariani, the Chief Financial Officer, sold 10,548 shares at $1.09 per share on August 19, 2025.

Analysts Set New Price Targets

On January 12, 2026, D. Boral Capital maintained its 'buy' rating on CTSO, setting a price target of $10. HC Wainwright & Co. maintained a 'hold' rating with a target of $0.75 on November 14, 2025. The consensus among analysts suggests varied expectations, with recommendations ranging from 'hold' to 'buy'.

Bottom Line

Phillip Chan's recent purchase of CTSO shares highlights his confidence in the company's prospects. Institutional investors are also actively adjusting their stakes, reflecting diverse strategies and expectations. Analysts remain divided, with some maintaining high targets while others take a more cautious stance. As always, it's important to remember that insider purchases and institutional moves are backward-looking and may not indicate future performance.